ストックスクリーナーアプリを入手
0.8239
2.07%
-0.0174
アフターアワーズ：
.81
-0.0139
-1.69%
前日終値:
$0.8413
開ける：
$0.8244
24時間の取引高:
142.46K
Relative Volume:
0.45
時価総額：
$68.57M
収益：
$3.91M
当期純損益:
$-206.53M
株価収益率:
-0.3319
EPS:
-2.4825
ネットキャッシュフロー:
$-167.78M
1週間 パフォーマンス:
-5.06%
1か月 パフォーマンス:
-11.03%
6か月 パフォーマンス:
-33.56%
1年 パフォーマンス:
-55.70%
1日の値動き範囲:
$0.781
$0.8342
1週間の範囲:
$0.781
$0.88
52週間の値動き範囲:
$0.76
$2.00
I Mab Adr Stock (IMAB) Company Profile
IMAB を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IMAB
I Mab Adr
|
0.8239 | 68.57M | 3.91M | -206.53M | -167.78M | -2.4825 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
I Mab Adr Stock (IMAB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-12-09 | 開始されました | Siebert Williams Shank | Buy |
| 2021-06-02 | 開始されました | Daiwa Securities | Buy |
| 2021-03-15 | 開始されました | Needham | Buy |
| 2021-03-03 | 繰り返されました | H.C. Wainwright | Buy |
| 2021-02-25 | 開始されました | Piper Sandler | Overweight |
| 2020-12-07 | 開始されました | H.C. Wainwright | Buy |
| 2020-07-27 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-02-12 | 開始されました | China Renaissance | Buy |
| 2020-02-11 | 開始されました | Jefferies | Buy |
すべてを表示
I Mab Adr (IMAB) 最新ニュース
I-Mab faces Nasdaq delisting over bid price rule By Investing.com - Investing.com South Africa
I-Mab faces Nasdaq delisting over bid price rule - Investing.com
I-Mab advances gastric cancer treatment with swift trial enrollment - Investing.com
I-Mab stock touches 52-week low at $0.76 amid market challenges - Investing.com India
I-Mab ADR (IMAB) stock analysis: A simple moving average approach - US Post News
Use of failure mode and effect analysis to improve the monoclonal antibody drugs management process in pharmacy intravenous admixture services - Nature
I-Mab Chairman plans $2 million ADS purchase - Investing.com India
I-Mab’s Third Quarter Results: Progress in Cancer Immunotherapies - MSN
I-Mab names Sean Fu as new CEO - Investing.com India
Invitation: Vallourec Q3 2024 Results ReleaseConference Call on Friday, November 15, 2024 - The Manila Times
I-Mab ADR (NASDAQ: IMAB) Stock: Investors Need To Know This - Stocks Register
Would I Buy Spectral AI Inc (NASDAQ: MDAI) Stock At Any Time In The Future? - Stocks Register
If You Don’t Buy Hub Cyber Security Ltd (NASDAQ: HUBC) Now, You’ll Kick Yourself Later - Stocks Register
Itau Unibanco Holding S.A. ADR (NYSE: ITUB) Still Pointing Upwards - Stocks Register
Is Veritone Inc’s (NASDAQ:VERI) Stock On The Decline? - Stocks Register
Cisco Systems, Inc. (NASDAQ: CSCO): What’s Next After The Stock Plunge? - Stocks Register
Should This Give Tandem Diabetes Care Inc (NASDAQ: TNDM) Investors Sleepless Nights? - Stocks Register
Kinross Gold Corp. (NYSE: KGC) Investors Should Be Worried About This. - Stocks Register
Where Do Analysts See Maravai LifeSciences Holdings Inc (NASDAQ: MRVI) Heading? - Stocks Register
Not A Good News For Keycorp (NYSE: KEY): The Stock Could Go Down -34.98 Percent More - Stocks Register
Analyst Forecast For Grab Holdings Limited (NASDAQ: GRAB) - Stocks Register
Asian Equities Traded in the US as American Depositary Receipts Advance in Thursday Trading - MSN
IMab (IMAB) Moves to Buy: Rationale Behind the Upgrade - Yahoo Finance
IMAB’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - The InvestChronicle
Company’s Banking Shares: Up -42.43% from 52-Week Low, But Can the Momentum Hold? - The InvestChronicle
IMAB’s price-to-sales ratio: A comparative analysis with its peers - US Post News
Piper Sandler maintains Overweight rating on I-Mab stock on drug data - Investing.com
I-Mab Reports 1H 2024 Financial Results, Pipeline Progress, and Business Updates - PR Newswire
Piper Sandler cuts I-Mab stock target to $10, keeps overweight rating - Investing.com
symbol__ Stock Quote Price and Forecast - CNN
Minnelide combined with anti-ANGPTL3-FLD monoclonal antibody completely protects mice with adriamycin nephropathy by promoting autophagy and inhibiting apoptosis - Nature
I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Year Ended December 31, 2022 - PR Newswire
Effects of a monoclonal antibody against (pro)renin receptor on gliomagenesis - Nature.com
Market Brief: Will the December CPI Report Help Further Tame Inflation Fears? - Morningstar
Morningstar’s Best- and Worst-Performing Stocks: 2022 - Morningstar
The Cheapest Stock in the World - Morningstar.ca
10 of the Cheapest Stocks of 2022 - Morningstar
Why Are Some China Healthcare Stocks Up 50%? - HK.Morningstar.com
Fig. 3 A Scatchard analysis of 125 I-trastuzumab binding to human... - ResearchGate
Anti-ANGPTL3-FLD monoclonal antibody treatment ameliorates podocyte lesions through attenuating mitochondrial damage - Nature
The Best- and Worst-Performing Stocks: Q3 2022 - Morningstar
Fig. 2 Flowchart of Sicilian adverse drug reaction (ADR) report... - ResearchGate
Markets Brief: How High Can Mortgage Rates Go? - Morningstar
New 5-Star Stocks - Morningstar
HFCAA News: 128 Chinese Stocks the SEC Could Delist - InvestorPlace
Safety Profile of Monoclonal Antibody Compared With Traditional Anticancer Drugs: An Analysis of Henan Province Spontaneous Reporting System Database - Frontiers
The Daily Biotech Pulse: AbbVie In-licenses I-Mab's Cancer Drug, Savara Pulls The Plug On Cystic Fibrosis Study - Yahoo Finance
I-MabADR to Host Earnings Call - AccessWire
Figure 1: Conventional antibody expression in E. coli. Most of the... - ResearchGate
Figure 2: Alternative antibody expression in E. coli cytoplasm.... - ResearchGate
Table 2 : The seven types of headache arising from abnormalities within... - ResearchGate
I Mab Adr (IMAB) 財務データ
収益
当期純利益
現金流量
EPS
1.05%
1.79%
大文字化:
|
ボリューム (24 時間):